scholarly journals EP.TH.3Male Breast Cancer: A Series of Three Extremely Rare Cases

2021 ◽  
Vol 108 (Supplement_7) ◽  
Author(s):  
Ahmed Latif ◽  
Amna Suliman ◽  
Anupama Nagarajakumar ◽  
Mihir Khan ◽  
Anna Metafa ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Papillary Carcinoma ◽  
Ductal Carcinoma ◽  
Case Series ◽  
Mucinous Carcinoma ◽  
Wall Thickening ◽  
Low Grade ◽  
Breast Cancers ◽  
History Of ◽  
One Year

Abstract Aims Male breast cancer (MBC) is rare and accounts for 1% of all breast cancers. We present a case series of three very rare histological subtype MBC within one year in a UK hospital. Methods We retrospectively identified all MBCs from the local breast cancer database. Their presentations, radiology and histopathology were analysed. Results Three MBCs were identified from 2019 to 2020. A healthy 28-year-old presented with a right breast lump. Ultrasound (USS) revealed a partially cystic 15mm U3 lesion. Mammography (MMG) was suggestive of gynaecomastia (M2). Biopsy was inconclusive. Diagnostic excision revealed Papillary Ductal Carcinoma in Situ (DCIS) with involved margin. Mastectomy and Sentinel Node Biopsy (SNB) confirmed low-grade Papillary DCIS. A 48-year-old with background of hyperlipidaemia presented with a 2-year history of left axillary lump. PET CT demonstrated an FDG-avid lesion. USS showed a superficial U3 28mm lesion. MMG showed a 34mm density (M4). Biopsy identified Mucinous Carcinoma. Wide Local Excision and SNB confirmed grade 2 Mucinous Carcinoma. A 75-year-old with history of cardiac disease, COPD and Type 2 Diabetes, presented with a right retro-areolar lump. MMG identified a 47mm mass (M4). USS showed a 41mm cystic lesion with wall thickening (U4). Cytology was inconclusive. Biopsy identified intra-cystic papillary carcinoma. Mastectomy and SNB confirmed intra-cystic papillary carcinoma. All three histological subtypes are extremely rare and account for less than 4% of all MBCs. Conclusions MBC is rare but increasing in incidence. More research and awareness are needed to minimise delays in diagnosis and treatment even in young men.

scholarly journals Invasive papillary ductal carcinoma of the breast: A case report

2020 ◽  
Vol 10 (1) ◽  
pp. 17
Author(s):  
Amani S Hadi ◽  
Gamal Abdul Hamid ◽  
Refaat Al-Areqee ◽  
Wafa Abdullah
Keyword(s):  
Papillary Carcinoma ◽  
Ductal Carcinoma ◽  
Radical Mastectomy ◽  
Residual Tumor ◽  
Excisional Biopsy ◽  
Breast Mass ◽  
Low Grade ◽  
Breast Cancers ◽  
History Of ◽  
Invasive Papillary Carcinoma

The general rate of intrusive papillary carcinoma (IPC) is uncommon, representing for less than 1-2 % of invasive breast cancers. They are most generally observed in postmenposal females and uncommon in males. Invasive papillary carcinomas are low grade tumors originating from large or dilated ducts. They are make out of all around outlined solid nodules of monotones neoplastic cell separated by network of fibrovascular cores, IPC is a remarkable sort of breast cancer and regarded of whether it is in-situ or invasive, it has brilliant prognosis. We presenting two cases of invasive papillary carcinoma in male and female; A case of 55years postmenoposal female who presented with history of left breast mass, which this mass notice after trauma same site for 1 year ago the mass gradually increase in size no tenderness, no signs of inflammation. Excisional biopsy was performed and specimen was histopathology diagnosed as invasive papillary carcinoma, left MRM was performed and histopathology diagnosis confirmed and without residual tumor seen in submitted slides and all submitted lymph nodes were free of tumor infiltration (0/14). IHC show ER and PR negative with HER-2 positive. The second case 70 years male presented with right breast mass and history of post-trauma since one year back with gradual increase in size, right radical mastectomy done and histopathology diagnosed as invasive papillary carcinoma, IHC was done ER and PR positive with HER2- negative.

Prevalence of BRCA2 mutations and other clinical characteristics in women with triple-negative breast cancer.

2014 ◽  
Vol 32 (26_suppl) ◽  
pp. 160-160
Author(s):  
Jennifer Chun ◽  
Freya Ruth Schnabel ◽  
Shira Schwartz ◽  
Jessica Billig ◽  
Karen Hiotis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
At Risk ◽  
Genetic Testing ◽  
Clinical Characteristics ◽  
Triple Negative ◽  
Ductal Carcinoma ◽  
Personal History ◽  
Breast Cancers ◽  
History Of ◽  
Brca2 Mutations

160 Background: Triple-negative breast cancers (TNBC) represent 10%–20% of invasive breast cancers. Current guidelines recommend genetic testing for women who are diagnosed with TNBC. Studies have shown that BRCA1 mutations are associated with TNBC, but there is little information on the relationship of BRCA2 mutations and TNBC. The purpose of this study was to look at the clinical characteristics of TNBC compared to non-TNBC in a cohort of women with newly diagnosed breast cancer. Methods: The Breast Cancer Database at our institution was queried for patients with invasive breast cancer. We included the following variables: age, race, BRCA1,2, tumor characteristics, and personal history of breast cancer (PHBC). Statistical analyses included Pearson’s Chi-Square and Fisher’s Exact Tests. Results: Out of a total of 1,332 women, 125 (9%) had TNBC. The median age for both TNBC and non-TNBC was 59 years. Majority of women had early stage breast cancer (92%) with ductal carcinoma (80%). There was a significantly higher proportion of Blacks and Asians with TNBC (p < 0.0001). Women with TNBC had higher Ki-67 (p < 0.0001). Within the TNBC group, there were 12 (29%) patients who tested positive for BRCA1,2 mutation and 23 (8%) who tested positive for BRCA 1,2 mutations in the non-TNBC group. Interestingly, BRCA1 was not associated with TNBC (p = 0.40) and BRCA2 was significantly associated with TNBC (p < 0.0001). We also found a higher proportion of TNBC in women who had a PHBC (p = 0.01). Conclusions: In our study, women with TNBC were similar in age to women who did not have TNBC. We found that the women with TNBC in our cohort had elevated rates of BRCA2 mutations. We also found that women with a personal history of breast cancer were at risk for developing TNBC. This may be related to the use of hormonal therapy that reduces the risk of ER/PR-positive tumors. Women of all ages are at risk for developing TNBC and older age at TNBC should not deter from genetic testing.

scholarly journals Neuroendocrine Differentiation in Breast Cancer: Clinicopathological Significance of Bcl-2 Positive Solid Papillary Carcinoma

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Yoichiro Okubo ◽  
Takuji Okubo ◽  
Yoshimi Okubo ◽  
Takao Ishiwatari
Keyword(s):  
Breast Cancer ◽  
Papillary Carcinoma ◽  
Neuroendocrine Tumors ◽  
Ductal Carcinoma ◽  
Neuroendocrine Differentiation ◽  
Prognostic Indicator ◽  
Low Grade ◽  
Term Survival ◽  
Solid Papillary Carcinoma ◽  
Poor Prognostic Indicator

Solid papillary carcinoma (SPC) is considered a rare malignant breast tumor. Maluf and Koerner first reported this disease entity as a special type of ductal carcinoma in situ with several characteristic histopathological features, including low-grade cellular atypia, intracellular or extracellular mucin deposition, and solid papillary growth pattern, as well as neuroendocrine differentiation. The present paper describes a case of SPC with bcl-2 expression, which is known as a marker for malignancy of neuroendocrine tumors. Interestingly, despite bcl-2 expression being a poor prognostic indicator of neuroendocrine tumors, the patient with this tumor has achieved long-term survival (approximately 6 years) at the time of writing this report. Because previous investigators reported that bcl-2 expression might play a role in the inhibition of the development of breast cancer, we suggest that bcl-2 expression might reflect a good prognosis in patients with SPC, rather than being a poor prognostic indicator, as it is in several types of neuroendocrine tumor. However, to confirm this hypothesis, further investigation is required.

scholarly journals Expressing Status and Correlation of ARID1A and Histone H2B on Breast Cancer

2016 ◽  
Vol 2016 ◽  
pp. 1-9 ◽  
Author(s):  
Yan Wu ◽  
Yan Gu ◽  
Shanyu Guo ◽  
Qiancheng Dai ◽  
Wei Zhang
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma ◽  
Expression Profiles ◽  
Gene Expression Profiles ◽  
Mucinous Carcinoma ◽  
Cancer Gene ◽  
Breast Cancers ◽  
Histone H2b ◽  
Oncomine Database ◽  
Breast Cancer Gene

ARID1A is one of the important cancer-related genes and regulates transcription of certain genes by altering chromatin structure. Inactivated mutations and decreased expression of ARID1A gene have been reported in several kinds of cancer. Histone H2B is a major component of chromatin and encoded by HIST1H2BE. The goal of the study is to evaluate expressing status of ARID1A and H2B as well as their correlation on breast cancer. Gene expression profiles of ARID1A and H2B on Oncomine database are analyzed. Tissue microarray of breast cancer was used for examination of ARID1A and H2B expression by immunohistochemistry. As a result, the disagreement of ARID1A expression was found, while HIST1H2BE expression is elevated in 4 out of 5 datasets on Oncomine database. There were 15 cases (20%) of breast cancers that were positive for ARID1A. Fifty-eight out of 75 cases of breast cancer (77.3%) were highly expressed for H2B protein and 17 cases (22.7%) were low expressed for H2B protein. All cases with ARID1A expression are overlapped with H2B high expression. Among 15 cases with ARID1A and H2B coexpression, 13 are invasive ductal carcinoma and 2 are mucinous carcinoma. Our results indicate that ARID1A gene may be involved in carcinogenesis of some subtypes of breast cancer.

Tubular carcinoma of the breast: A single institution's experience of prognosis.

2015 ◽  
Vol 33 (28_suppl) ◽  
pp. 37-37
Author(s):  
William P Boyan ◽  
Michael Farr ◽  
Brian Shea ◽  
Manpreet Kohli ◽  
Ernest Ginalis
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma ◽  
Treatment Plan ◽  
Endocrine Treatment ◽  
Breast Cancers ◽  
Carcinoma Of The Breast ◽  
Tubular Carcinoma ◽  
Care Givers ◽  
One Year ◽  
Evidenced Based

37 Background: Tubular carcinoma is a less aggressive form of breast cancer which emcompasses 1-4% of invasive breast cancer. Prior studies have shown a nearly 100% 15 year survival rate for tubular carcinoma compared to the 89.2% five year survival of all breast cancers. The question asked is if these two cancers should be treated the same. The goal of oncologic treatment is to maximize survival while limiting side effects. At the very least, care givers should be able to give prognostic encouragement to patients based on this less aggressive histological subtype. Methods: A retrospective study of charts for tubular carcinoma of the breast from 2000 to 2015 were analyzed. A total of 57 patients were captured. All relevant aspects of the patients history, as well as therapies rendered and outcomes were documented. The aim of our study was compare treatment outcomes in our group of tubular carcinomas to that of breast cancer as a whole. Results: A total of 57 patients were diagnosed and treated for tubular carcinoma of the breast between 2000 and 2015 from a single institution. Of the 57 patients, local recurrence was seen in two patients. The first patient underwent lumpectomy, endocrine and radiation therapy then recurred as an invasive ductal carcinoma 12 years later. A second patient underwent lumpectomy with endocrine treatment but refused radiation, recurring as a tubular carcinoma 10 months later. In our 16 year sample the recurrence rate was 3.5% or 1.75% recurring as tubular. This is lower than the rates of recurrence of all breast cancer. To this date there were no cancer related mortalities in our group. Conclusions: A look into our institution’s data supported the notion that tubular carcinoma of the breast is a less aggressive histological type. Of our 57 cases and mean follow up time of six years ranging from one year to fifteen, only two recurrences (3.5%) were noted and there was no cancer related mortalities. Interestingly only one (1.75%) recurred as tubular carcinoma. Without controlling for adjuvant therapy, recommendations cannot be made for a less aggressive treatment plan at this point. Based on this study and others like it physicians can give evidenced based favorable prognosis when the diagnosis of tubular carcinoma is made.

Overdiagnosis and Overtreatment of Breast Cancer

2012 ◽  
pp. e40-e45
Author(s):  
Michael Alvarado ◽  
Elissa Ozanne ◽  
Laura Esserman
Keyword(s):  
Breast Cancer ◽  
Lower Risk ◽  
Ductal Carcinoma ◽  
Early Stage ◽  
Invasive Cancer ◽  
Molecular Testing ◽  
Low Grade ◽  
Breast Cancers ◽  
Molecular Tests

Overview: Breast cancer is the most common cancer in women. Through greater awareness, mammographic screening, and aggressive biopsy of calcifications, the proportion of low-grade, early stage cancers and in situ lesions among all breast cancers has risen substantially. The introduction of molecular testing has increased the recognition of lower risk subtypes, and less aggressive treatments are more commonly recommended for these subtypes. Mammographically detected breast cancers are much more likely to have low-risk biology than symptomatic tumors found between screenings (interval cancers) or that present as clinical masses. Recognizing the lower risk associated with these lesions and the ability to confirm the risk with molecular tests should safely enable the use of less aggressive treatments. Importantly, ductal carcinoma in situ (DCIS) lesions, or what have been called stage I cancers, in and of themselves are not life-threatening. In situ lesions have been treated in a manner similar to that of invasive cancer, but there is little evidence to support that this practice has improved mortality. It is also being recognized that DCIS lesions are heterogeneous, and a substantial proportion of them may in fact be precursors of more indolent invasive cancers. Increasing evidence suggests that these lesions are being overtreated. The introduction of molecular tests should be able to help usher in a change in approach to these lesions. Reclassifying these lesions as part of the spectrum of high-risk lesions enables the use of a prevention approach. Learning from the experience with active surveillance in prostate cancer should empower the introduction of new approaches, with a focus on preventing invasive cancer, especially given that there are effective, United States Food and Drug Administration (FDA)-approved breast cancer preventive interventions.

An unusual middle-ear mass

2009 ◽  
Vol 124 (1) ◽  
pp. 108-110 ◽  
Author(s):  
M Muller ◽  
I Zammit-Maempel ◽  
J Hill ◽  
B Wilkins
Keyword(s):  
Case Report ◽  
Papillary Carcinoma ◽  
Middle Ear ◽  
Endolymphatic Sac ◽  
Low Grade ◽  
Complete Replacement ◽  
Glomus Tympanicum ◽  
History Of ◽  
Petrous Temporal Bone ◽  
One Year

AbstractObjective:We describe a case of endolymphatic sac tumour confined to the middle ear, which radiologically mimicked a glomus tympanicum, in a 58-year-old woman with tinnitus.Case report:A 58-year-old woman presented with a one-year history of right-sided tinnitus. The clinical, radiological and surgical features were felt to be in keeping with a glomus tympanicum. However, the histopathological picture was that of a low grade papillary carcinoma of the endolymphatic sac, i.e. an endolymphatic sac tumour.Conclusion:Endolymphatic sac tumours are classically locally aggressive and centred around the petrous temporal bone. Further growth results in complete replacement of the mastoid and petrous pyramid by tumour. To the best of our knowledge, there have been no previous reports of an endolymphatic sac tumour located solely within the hypo- and epitympanum of the middle ear.

scholarly journals Relationship Between Anthropometric Factors and Risk of Second Breast Cancer Among Women With a History of Ductal Carcinoma In Situ

2018 ◽  
Vol 2 (2) ◽  
Author(s):  
Meghan R Flanagan ◽  
Mei-Tzu C Tang ◽  
Michelle L Baglia ◽  
Peggy L Porter ◽  
Kathleen E Malone ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Breast Cancers ◽  
Increased Risk ◽  
History Of ◽  
Second Breast Cancer ◽  
The Impact

AbstractBackgroundWomen with ductal carcinoma in situ (DCIS) have an elevated risk of a second breast cancer, but few data are available regarding the impact of modifiable lifestyle factors on this risk.MethodsIn a population-based case–control patient study of women with a history of DCIS in western Washington diagnosed between 1996 and 2013, 497 patients diagnosed with DCIS and a second ipsilateral or contralateral invasive or in situ breast cancer were enrolled. There were 965 matched control patients with one DCIS diagnosis. Associations between anthropometric factors and risk of an invasive or in situ second breast cancer event were evaluated using conditional logistic regression. Statistical tests were two-sided.ResultsObesity (body mass index [BMI] ≥ 30 kg/m2) at initial DCIS diagnosis was associated with a 1.6-fold (95% confidence interval [CI] = 1.2 to 2.2) increased risk of any second breast cancer and a 2.2-fold increased risk of a contralateral second breast cancer (95% CI = 1.4 to 3.3) compared with normal weight women (BMI < 25 kg/m2). BMI and weight, both at initial DCIS diagnosis and at the time of the second breast cancer diagnosis, were positively associated with risk of any second and second invasive breast cancers (odds ratio = 1.01–1.04, all P ≤ .03).ConclusionsAlthough additional confirmatory studies are needed, obesity appears to be an important contributor to the risk of second breast cancers within the growing population of women with DCIS. This has potential clinical relevance with respect to identifying which women with a history of DCIS may require more careful monitoring and who may benefit from lifestyle modifications.

Adjuvant paclitaxel, capecitabine, and trastuzumab for HER-positive breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e11526-e11526
Author(s):  
H. Jouhadi ◽  
A. Benider
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Cardiac Toxicity ◽  
Ductal Carcinoma ◽  
Metastatic Breast ◽  
Breast Cancers ◽  
Treatment Standards ◽  
International Research Group ◽  
Equivalent Efficacy ◽  
One Year

e11526 Background: Anthracyclines are integral components of most adjuvant chemotherapy regimens for surgically removed early breast cancer and are central to the accepted treatment standards. Recently the standard anthracycline regimen of doxorubicin plus cyclophosphamide was found to be inferior in preventing recurrence of breast cancer when compared to cyclophosphamide and docetaxel, questioning the necessity to expose patients to the potential cardiotoxicity of anthracycline in the adjuvant setting. Trastuzumab, cornerstone of treatment of breast cancers that overexpress HER2 produces Unfortunately, in combination with anthracyclines a high incidence of cardiotoxicity as seen in early trials of metastatic breast cancer. The trastuzumab adjuvant trial 006 from the Breast Cancer International Research Group shows for the first time that a nonanthracycline-containing regimen with trastuzumab has equivalent efficacy in decreasing the recurrence of breast cancer, with less incidence of cardiotoxicity when compared to anthracycline-containing trastuzumab adjuvant regimens. Methods: Our trial compared two adjuvant schemas of adjuvant chemotherapy arm1: paclitaxel(day 1-day 21: 6 courses), capecitabine(day1 to day 14: 6 courses) and trastuzumab (day 1 to day 21 for one year). Arm2: 4AC plus 4 TH plus trastuzumab for one year. Inclusion criteria: HER positive invasive ductal carcinoma, no lymphe node invaded at axillary dissection and no metatstasis, Negative ER and PR receptors Goal of study: evaluate efficacy and cardiac toxicity Results: From 2004 to 2005: 30 patient were included in each arm. After 3 years: DFS was respectively 93% in first arm and 90% in Second arm Four women developed severe cardiac toxicity in arm 2 versus no one in arm1 Conclusions: There is no difference in efficacy between the two arms but a significant increase in cardiac toxicity in the second arm. No significant financial relationships to disclose.

scholarly journals Estrogens and Progestogens in Triple Negative Breast Cancer: Do They Harm?

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2506
Author(s):  
Mark van Barele ◽  
Bernadette A. M. Heemskerk-Gerritsen ◽  
Yvonne V. Louwers ◽  
Mijntje B. Vastbinder ◽  
John W. M. Martens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Hormone Replacement ◽  
Breast Cancers ◽  
Younger Women ◽  
Alternative Pathways ◽  
Increased Risk ◽  
History Of ◽  
Hormone Sensitive

Triple-negative breast cancers (TNBC) occur more frequently in younger women and do not express estrogen receptor (ER) nor progesterone receptor (PR), and are therefore often considered hormone-insensitive. Treatment of premenopausal TNBC patients almost always includes chemotherapy, which may lead to premature ovarian insufficiency (POI) and can severely impact quality of life. Hormone replacement therapy (HRT) is contraindicated for patients with a history of hormone-sensitive breast cancer, but the data on safety for TNBC patients is inconclusive, with a few randomized trials showing increased risk-ratios with wide confidence intervals for recurrence after HRT. Here, we review the literature on alternative pathways from the classical ER/PR. We find that for both estrogens and progestogens, potential alternatives exist for exerting their effects on TNBC, ranging from receptor conversion, to alternative receptors capable of binding estrogens, as well as paracrine pathways, such as RANK/RANKL, which can cause progestogens to indirectly stimulate growth and metastasis of TNBC. Finally, HRT may also influence other hormones, such as androgens, and their effects on TNBCs expressing androgen receptors (AR). Concluding, the assumption that TNBC is completely hormone-insensitive is incorrect. However, the direction of the effects of the alternative pathways is not always clear, and will need to be investigated further.

Sign in / Sign up

Export Citation Format

Share Document